Designation of Licensed Compounds Sample Clauses

Designation of Licensed Compounds. At the request of Solvay, the Research Committee will review and consider the pertinent confirmatory data with respect to each group of Available Compounds (as determined by the Research Committee under Section 3.4.) and, if the activity of the resynthesized compound or compounds has been confirmed, designate the Available Compounds within the group as "Licensed Compounds" under this Agreement, whereupon Solvay shall disclose the Target and level of activity for the Licensed Compounds and, at the request of Solvay, ArQule shall disclose the structures but not the locations of the other ArQule Compounds in the same Mapping Array Library as the Licensed Compounds. Upon the designation of an Available Compound as a Licensed Compound and the disclosure by Solvay of the Target and level of activity, the licenses set forth in Section 7.2 shall automatically apply, and ArQule shall confirm such license in writing. If the Research Committee determines that the activity of the resynthesized compound or compounds has not been confirmed, then the Available Compounds within the group shall automatically lose their reserved status and Solvay shall have no further rights to such compounds.
Sample 1Sample 2
AutoNDA by SimpleDocs
Designation of Licensed Compounds. At the request of Sankyo, the Research Committee will review and consider the pertinent confirmatory data and, after consideration, designate confirmed Available Compounds as "Licensed Compounds" under this Agreement. Sankyo acknowledges that an Active Compound that Sankyo desires to designate as a Licensed Compound may not retain its status as an Available Compound if the reservation period expired ----------------------- Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions. for that Active Compound. Therefore, if an Active Compound is no longer reserved (i.e., the reservation period expired), ArQule must determine whether that Active Compound is still an Available Compound before the Research Committee may designate the Active Compound as a Licensed Compound. Upon the designation of an ArQule Compound as a Licensed Compound, the licenses set forth in Section 6.2. shall automatically apply. All Licensed Compounds from a Mapping Array Library that share activity for the same Target shall form a Licensed Compound Set for the purposes of this Agreement.
Sample 1
Designation of Licensed Compounds. At any time during the Research Term or within 90 days after its expiration or its termination pursuant to Section 3.6 (but not any other termination of the Research Term or this Agreement), [***] in [***] of [***] upon which [***] or [***] to [***]. If [***] such [***], then within [***] or [***] of the [***], [***] ([***], as applicable) shall [***] of [***]. [***] of [***], such [***] shall [***] of [***]. The [***] with respect to [***] may be [***], but each [***] with respect to [***] initiated shall be subject to milestone and royalty payment obligations under Article 5 hereof.
Sample 1
Designation of Licensed Compounds. The Parties hereby acknowledge and agree that Sugen, in making its determination as to whether to designate any Active Sugen Compound as a Licensed Compound, shall use the good scientific and business criteria set forth on Exhibit C attached hereto, it being the intention of the Parties that such criteria shall be used as the basis for determining whether any Active Sugen Compound shall also be designated as a Licensed Compound.
Sample 1
Designation of Licensed Compounds. At the request of Sankyo, the Research Committee will review and consider the pertinent confirmatory data and, after consideration, designate confirmed Available Compounds as "Licensed Compounds" under this Agreement. Sankyo acknowledges that an Active Compound that Sankyo desires to designate as a Licensed Compound may not retain its status as an Available Compound if the reservation period expired for that Active Compound. Therefore, if an Active Compound is no longer reserved (i.e., the reservation period expired), ArQule must determine whether that Active Compound is still an Available Compound before the Research Committee may designate the Active Compound as a Licensed Compound. Upon the designation of an ArQule Compound as a Licensed Compound, the licenses set forth in Section 6.2. shall automatically apply. All Licensed Compounds from a Mapping Array Library that share activity for the same Target shall form a Licensed Compound Set for the purposes of this Agreement.
Sample 1
Designation of Licensed Compounds. At any time after SB has screened the Compass Array Library and the Mapping Array Libraries corresponding to Available Compounds identified in the Compass Array Library (i.e., confirmation in secondary screens is unnecessary), SB may select any reserved Available Compound or reserved Inactive ArQule Compound as a Licensed Compound under this Agreement. In such event, SB shall provide ArQule with written notice of its selection and ArQule will change the status of such ArQule Compounds from "reserved" to "licensed". Upon the designation of an ArQule Compound as a Licensed Compound, the licenses set forth in Subsection 5.2 shall automatically become effective. All Licensed Compounds from a Mapping Array Library that share activity for the same Target, ***** shall form a Licensed Compound Set for the purposes of this Agreement.
Sample 1
Designation of Licensed Compounds. At any time after SB has screened the Compass Array Library and the Mapping Array Libraries corresponding to Available Compounds identified in the Compass Array Library (i.e., confirmation in secondary screens is unnecessary), SB may select any reserved Available Compound or reserved Inactive ArQule Compound as a Licensed Compound under this Agreement. In such event, SB shall provide ArQule with written notice of its selection and ArQule will change the status of such ArQule Compounds from "reserved" to "licensed". Upon the designation of an ArQule Compound as a Licensed Compound, the licenses set forth in Subsection 5.2 shall automatically become effective. All Licensed Compounds from a Mapping Array Library that share activity for the same Target, [*****] shall form a Licensed Compound Set for the purposes of this Agreement. ---------------------- CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.
Sample 1
AutoNDA by SimpleDocs
Designation of Licensed Compounds 
Sample 1

Related to Designation of Licensed Compounds

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Patent Rights The term “Licensed Patent Rights” shall mean rights arising out of or resulting from:

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

Time is Money Join Law Insider Premium to draft better contracts faster.